<DOC>
	<DOCNO>NCT02616666</DOCNO>
	<brief_summary>A trial patient type 2 diabetes mellitus evaluate comparative effectiveness dapagliflozin Standard Care ( SOC ) .</brief_summary>
	<brief_title>A Pragmatic Trial Evaluate Comparative Effectiveness Between Dapagliflozin Standard Care Type 2 Diabetes Patients ( DECIDE Study )</brief_title>
	<detailed_description>A longitudinal , open label , pragmatic randomize 104 week multicentre trial patient type 2 diabetes mellitus evaluate comparative effectiveness dapagliflozin Standard Care ( SOC ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>For inclusion study patient fulfil follow criterion time screening : 1 . Provision inform consent prior study specific procedures 2 . Females male age ≥18 year ≤ 75 year 3 . Diagnosed Type 2 Diabetes Mellitus . 4 . Uncontrolled firstline metformin treatment , define ≥8 week maximum tolerate dose metformin HbA1c &gt; 6.5 % . 5 . Ability read write judge investigator . Patients enter study follow exclusion criterion fulfil : 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) 2 . Previous enrolment randomization present study 3 . Age &gt; 75 year 4 . Pregnancy/active breast feeding time inclusion 5 . Known moderate severe renal impairment ( eGFR &lt; 60ml/min ) . 6 . Participation interventional clinical trial ≤ 3 month enrolment . 7 . Unsuitable participate mental health ground , judge investigator . 8 . Physician decision use , second line treatment , insulin , GLP1 agonist compound SGLT2 inhibitor different dapagliflozin . 9 . Presence characteristic product study contraindicate , per current label .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Randomised</keyword>
	<keyword>Pragmatic</keyword>
	<keyword>Standard Care</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>FORXIGA</keyword>
</DOC>